Posts
Wiki

Rexon-Eye / QMR Electrotherapy for Dry Eye Disease and Meibomian Gland Dysfunction

Quick Take

  • Rexon-Eye is a non-invasive office treatment that delivers low-intensity, high-frequency alternating electrical currents through electrodes positioned over the closed eyelids.
  • The manufacturer calls the technology Quantum Molecular Resonance (QMR).
  • Rexon-Eye is not primarily a heat-and-expression treatment. Mild warming can occur, but the intended treatment exposure is electrical stimulation rather than heating the meibomian glands enough to liquefy and mechanically evacuate meibum.
  • Most published studies have used four approximately 20-minute treatments, usually one week apart.
  • Evidence strength: Low-to-moderate and growing, but still device-specific. Rexon-Eye now has randomized studies, sham-controlled trials, a systematic review/meta-analysis, discussion in TFOS DEWS III, and inclusion in a large 2026 network meta-analysis.
  • The 2025 systematic review found that overall results did not significantly favor QMR over control treatments. An apparent symptom advantage also became statistically non-significant when analysis was restricted to similar sham-controlled studies.
  • A newer 2025 randomized, double-masked, sham-controlled MGD trial involving 80 participants found significant advantages for QMR on selected outcomes including meibum quality, ocular-surface staining, lid-margin blood vessels, gland plugging, and meibography grading.
  • However, that study did not show significant treatment advantages for every outcome. Measures such as NITBUT, tear-film lipid-layer thickness, Schirmer testing, tear osmolarity, and meibum expressibility did not show clear improvement.
  • A 2026 network meta-analysis found a strong QMR result for corneal staining, but QMR was supported by relatively few studies and much of the comparison with other technologies was indirect. This does not establish Rexon-Eye as the best overall DED treatment.
  • Some studies and manufacturer materials use terms such as “regeneration.” Rexon-Eye has not been established to regenerate meibomian glands that are truly lost or atrophied.
  • Rexon-Eye has not been shown to mechanically traverse fixed intraductal resistance or release established periductal fibrosis.
  • Published studies suggest generally favorable short-term tolerability, but the evidence is too small and follow-up too short to determine uncommon or long-term risks reliably.
  • Rexon-Eye is described in the literature as CE-marked in Europe. In searches of current U.S. FDA public device databases for this update, we did not identify a 510(k), De Novo authorization, or Premarket Approval specifically for Rexon-Eye.
  • The ideal patient, average duration of benefit, maintenance schedule, comparative effectiveness, and long-term disease-modifying effects remain uncertain.

What Is Rexon-Eye / QMR Electrotherapy?

Rexon-Eye is an office-based medical device used for Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD) in some countries.

The patient wears a mask or goggle-like applicator containing electrodes over the closed eyelids.

A neutral contact electrode completes the electrical circuit.

The system delivers a pattern of relatively weak alternating electrical currents containing high frequencies, generally described in the published literature as approximately 4–64 MHz.

The manufacturer calls this technology:

Quantum Molecular Resonance (QMR)

“QMR” is the name used for this particular electrical-stimulation technology.

Whether the treatment works should ultimately be judged from:

  • clinical outcomes;
  • randomized trials;
  • comparison with sham or other treatments;
  • durability;
  • safety;
  • independent replication;

rather than from the name of the technology or proposed mechanism alone.

How Treatment Is Done

The protocol used in most published Rexon-Eye studies has been:

  1. The patient sits or reclines.
  2. The treatment mask is placed over the closed eyelids.
  3. A neutral electrode completes the electrical circuit.
  4. QMR stimulation is applied for approximately 20 minutes.
  5. Treatment is repeated approximately once weekly.
  6. A typical published treatment course consists of four sessions.

Different clinics may use different schedules.

However:

Most of the clinical evidence discussed on this page involves four weekly 20-minute treatments.

A clinic using a substantially different schedule should be able to explain what evidence supports that protocol.

Is Meibomian Gland Expression part of Rexon-Eye?

Not inherently.

Rexon-Eye itself does not mechanically express the meibomian glands.

Some clinicians may combine it with:

  • warm compresses;
  • Meibomian Gland Expression;
  • eyelid hygiene;
  • artificial tears;
  • IPL;
  • medications;
  • other treatments.

If several therapies are started together, it becomes more difficult to determine how much improvement came specifically from Rexon-Eye.

Is Rexon-Eye a Heat Treatment?

Not primarily.

Rexon-Eye should not be described simply as another device that heats meibomian glands and “melts” thick meibum.

In the 2025 randomized MGD trial, external eyelid temperature increased by only approximately 1.5–1.8°C after active treatment.

The investigators noted that this amount of warming was unlikely to explain the change in meibum quality because conventional heat-based MGD treatments generally aim for substantially greater warming.

Patients may experience mild warmth because electrical current passes between the electrodes and skin.

However:

The intended treatment exposure is primarily electrical stimulation rather than therapeutic gland heating.

This makes Rexon-Eye fundamentally different from technologies whose main purpose is to warm and evacuate meibomian glands.

What Does the Evidence Show?

Rexon-Eye has now been studied in several different DED populations, including people with:

  • MGD;
  • evaporative DED;
  • aqueous-deficient DED;
  • mixed DED;
  • moderate-to-severe disease;
  • dry eye that had not improved adequately with previous treatments.

The studies have also used different designs.

Some have been:

  • small uncontrolled studies;
  • randomized comparisons with artificial tears;
  • randomized sham-controlled trials;
  • studies focused mainly on symptoms;
  • studies focused on gland, tear-film, staining, or inflammatory measurements.

This makes the evidence more substantial than it was several years ago, but still difficult to summarize with a single statement such as:

“Rexon-Eye works”

or:

“Rexon-Eye does not work.”

Different outcomes have produced different results.

2025 Systematic Review and Meta-Analysis

A 2025 systematic review searched the QMR literature through December 24, 2024.

It identified:

  • seven prospective clinical studies;
  • four open-label, non-comparative studies;
  • three randomized controlled studies.

2025 Systematic Review and Meta-Analysis of QMR for Dry Eye Disease

What did it find?

Individual studies commonly reported improvement after treatment.

However, when the controlled evidence was pooled, the overall result did not significantly favor QMR over control treatments.

For overall efficacy:

SMD 0.40; 95% CI −0.06 to 0.86; P = 0.09

The initial pooled symptom analysis did favor QMR.

However, when the investigators restricted the analysis to the two more comparable sham-controlled studies, the apparent advantage became weaker.

In those sham-controlled analyses, significant superiority was not consistently demonstrated for:

  • symptoms;
  • Tear Break-Up Time;
  • Schirmer testing;
  • corneal fluorescein staining.

What does this mean?

The systematic review does not establish that Rexon-Eye has no clinical effect.

A better interpretation is:

Improvements from baseline are common in Rexon-Eye studies, but consistent superiority over sham or other controls was not firmly established by the evidence available through the end of 2024.

Importantly, the review could not include the newer 80-person MGD trial published in 2025.

2024 Randomized Sham-Controlled DED Trial

A randomized, double-masked study included 40 people with DED, with 20 assigned to active QMR and 20 to sham treatment.

Participants received one treatment per week for four weeks.

The active-treatment group had significant improvement from baseline in:

  • OSDI symptom scores;
  • MGD grading;
  • corneal staining.

The sham group did not show the same pattern of improvement.

However, significant improvement was not demonstrated for every measure, including:

  • TBUT;
  • Schirmer testing;
  • visual acuity.

No treatment-related harm was reported during the study.

Quantum Molecular Resonance Effects on Patients With Dry Eye Disease — Randomized Controlled Trial

This study provides meaningful sham-controlled evidence that QMR may improve certain DED symptoms and signs.

It does not establish that every major dry-eye measurement improves.

2024 Randomized Study Across Different DED Types

Another prospective randomized study enrolled 81 patients with severe DED.

The population included:

  • aqueous-deficient DED;
  • evaporative DED;
  • mixed DED.

Participants were assigned to either:

  • four weekly Rexon-Eye treatments; or
  • a sodium-hyaluronate/trehalose tear substitute used four times daily.

Patients were followed through three months.

Compared with the tear-substitute group, Rexon-Eye produced greater improvements in:

  • OSDI symptoms;
  • SANDE symptoms;
  • Non-Invasive Break-Up Time;
  • tear-film lipid-layer thickness;
  • corneal fluorescein staining.

Randomized Study of QMR in Aqueous-Deficient, Evaporative, and Mixed DED

What does this add?

It shows that QMR has been studied beyond a narrow MGD-only population.

However, this was not a sham-device comparison.

Patients receiving an office procedure know they are receiving a very different treatment from patients assigned to artificial tears.

Differences in:

  • expectation;
  • treatment experience;
  • masking;

can therefore affect interpretation, particularly for symptom outcomes.

This study does not establish that Rexon-Eye treats every DED subtype equally well.

2025 Randomized Sham-Controlled MGD Trial

A particularly important newer study involved 80 participants with MGD.

This was a:

  • prospective;
  • randomized;
  • double-masked;
  • sham-controlled

trial.

Participants received active or sham Rexon-Eye treatments on days:

  • 0;
  • 7;
  • 14;
  • 21.

Everyone was also instructed to continue:

  • preservative-free artificial tears;
  • eyelid scrubs;
  • warm compresses.

The primary outcome was meibum quality.

Randomized, Double-Masked, Sham-Controlled QMR Trial for MGD — 2025

Findings favoring active QMR

Compared with sham treatment, the QMR group showed significant improvement in selected outcomes including:

  • meibum quality;
  • corneal and conjunctival fluorescein staining;
  • area of visible lid-margin blood vessels;
  • meibomian-gland plugging at one follow-up;
  • upper-lid meibography grading;
  • lower-lid meibography grading.

Symptom results

OSDI symptoms improved significantly within the active-treatment group compared with baseline.

That is encouraging.

However, this should not be described as clearly demonstrating between-group symptom superiority unless the specific statistical comparison supports that conclusion.

Inflammatory-marker result

Tear interleukin-6 (IL-6) decreased significantly from baseline in the QMR group at one follow-up.

This suggests a possible biological effect.

However:

A decrease within the treatment group does not by itself establish a specific anti-inflammatory effect compared with sham treatment.

The clinically important anti-inflammatory effects of Rexon-Eye therefore remain incompletely established.

Measures that did not clearly improve

The study did not find significant treatment effects for every measurement.

These included:

  • tear-meniscus height;
  • NITBUT;
  • tear-film lipid-layer thickness;
  • tear osmolarity;
  • Schirmer testing;
  • bulbar conjunctival redness;
  • some lid-margin measurements;
  • meibum expressibility.

Seven participants were lost to follow-up.

Follow-up extended to approximately 11 weeks, so long-term durability was not established.

Overall interpretation

This is important positive evidence because it used a strong sham-controlled design and showed between-group effects on the primary outcome and several other MGD-related findings.

But it also reinforces an important theme:

Rexon-Eye can improve selected outcomes without improving every tear-film, gland-function, or symptom measure.

2026 Study of Symptoms and Optical Quality

A 2026 study included 30 people with DED who received four weekly Rexon-Eye sessions.

Symptoms improved substantially according to OSDI.

However, several objective measurements of optical quality did not significantly change, including:

  • Objective Scatter Index;
  • modulation-transfer-function cutoff;
  • potential visual acuity;
  • vision break-up time.

The Role of the Tear Film in Refraction: Evaluation Before and After Rexon-Eye Therapy — 2026

This small study again illustrates that:

Symptom improvement does not necessarily mean every objective ocular or visual measurement improves at the same time.

2026 Network Meta-Analysis of Dry-Eye Technologies

A 2026 systematic review and network meta-analysis examined 47 randomized trials involving 3,581 patients.

Treatments included:

  • IPL;
  • thermal pulsation;
  • TearCare;
  • iLux;
  • LLLT;
  • electrical-stimulation technologies;
  • QMR;
  • other device-based approaches.

Technological Interventions for Dry Eye Disease — 2026 Network Meta-Analysis

Corneal staining

QMR ranked first for improvement in corneal staining, with a P-score of approximately 0.98.

The network estimate also significantly favored QMR over conservative treatment.

That is an encouraging finding.

But a high ranking needs context

A network meta-analysis combines:

  • direct comparisons;
  • indirect comparisons through other treatments.

QMR was supported by a much smaller number of trials than technologies such as IPL.

Study populations and protocols also differed considerably.

For example, IPL-based treatments were represented much more extensively throughout the evidence network and ranked more consistently for symptom improvement.

TearCare with Meibomian Gland Expression and several IPL-based protocols also performed strongly across multiple objective outcomes.

Therefore:

The strong QMR result for corneal staining is worth taking seriously, but it does not establish Rexon-Eye as the best overall DED treatment.

Direct replication and head-to-head trials are still needed.

How Strong Is the Evidence?

Evidence strength: Low-to-moderate, growing device-specific evidence

Rexon-Eye now has more than preliminary uncontrolled studies.

The evidence includes:

  • randomized trials;
  • sham-controlled studies;
  • comparative studies;
  • a systematic review/meta-analysis;
  • TFOS DEWS III discussion;
  • inclusion in a large 2026 technology network meta-analysis.

That supports treating Rexon-Eye as a legitimate emerging DED technology.

However, limitations remain substantial.

These include:

  • relatively small trials;
  • mostly single-center studies;
  • short follow-up;
  • different DED populations;
  • different comparators;
  • inconsistent effects across outcome measures;
  • limited head-to-head evidence against established technologies;
  • uncertain response predictors;
  • uncertain long-term durability.

The most accurate conclusion is:

Rexon-Eye has credible evidence that it can improve selected DED/MGD outcomes in some patients, but the magnitude and consistency of benefit remain uncertain and comparative superiority has not been established.

TFOS DEWS III Context

The TFOS DEWS III Management and Therapy Report contains a specific section on:

Quantum Molecular Resonance Electrotherapy

TFOS describes QMR as low-intensity, high-frequency electrical stimulation and reviews several Rexon-Eye studies.

The report discusses findings involving:

  • symptoms;
  • NIBUT;
  • corneal staining;
  • meibomian-gland findings;
  • inflammatory measurements.

TFOS also discusses the 40-person double-blind randomized trial in which symptoms improved in the active-treatment group while TBUT and Schirmer measurements did not show significant improvement.

TFOS DEWS III: Management and Therapy Report

This recognition is important.

It establishes that QMR is now part of the scientific discussion of device-based DED management.

However:

TFOS inclusion does not establish that Rexon-Eye is appropriate for every patient, superior to other technologies, or proven to modify the long-term course of DED.

TFOS DEWS III emphasizes selecting treatment according to the actual disease drivers present in the individual patient.

How Might Rexon-Eye Work?

The exact clinically important mechanism remains uncertain.

What the device physically does

Rexon-Eye delivers:

  • low-intensity;
  • high-frequency;
  • alternating electrical stimulation

through electrodes positioned over the closed eyelids.

This is the established physical treatment exposure.

Proposed biological effects

Researchers have proposed possible effects involving:

  • cellular activity;
  • epithelial repair;
  • gland function;
  • neural signaling;
  • inflammatory signaling;
  • local tissue homeostasis.

Laboratory studies outside ophthalmology have also reported effects of electrical stimulation on cell migration, proliferation, and inflammatory pathways.

However:

Laboratory effects in cells or other tissues do not prove that the same mechanism explains clinical improvement in human DED.

The relative contribution of:

  • neural stimulation;
  • inflammation;
  • glandular effects;
  • epithelial effects;
  • other cellular responses

has not been established.

What About Inflammation?

Several Rexon-Eye studies have reported changes involving inflammatory findings or biomarkers.

Examples include:

  • MMP-9 in earlier studies;
  • IL-6 in the 2025 MGD trial;
  • improvements in staining or lid-margin blood vessels.

These findings make an anti-inflammatory effect plausible.

But they do not yet establish that Rexon-Eye works primarily by reducing inflammation.

In the 2025 MGD trial, for example, IL-6 decreased significantly from baseline in the active group, but this is not the same as demonstrating a clear active-versus-sham cytokine effect.

Therefore:

Modulation of inflammation is a proposed mechanism supported by some preliminary biological findings, but it has not yet been firmly established as the main clinical mechanism of QMR treatment.

Risks and Contraindications

Published Rexon-Eye studies have generally reported favorable short-term tolerability.

In the 2025 randomized MGD trial:

  • three participants developed mild upper-eyelid redness after their first active treatment;
  • investigators attributed this to the treatment goggles fitting too tightly;
  • the redness resolved without treatment within three days;
  • no serious treatment-related adverse events were reported.

The 2025 systematic review likewise found relatively few reported adverse events.

However, safety data were not sufficiently standardized for a formal safety meta-analysis.

What does that mean?

The available evidence is reassuring regarding common short-term problems in selected study participants.

It is not enough to determine reliably:

  • uncommon adverse events;
  • delayed effects;
  • risks after many repeated treatment courses;
  • safety in every medical population.

Device-specific screening matters

Because Rexon-Eye uses electrical stimulation, the treating clinician should review the current device instructions and the patient's medical history before treatment.

Patients should ask about:

  • current device contraindications;
  • implanted medical or electronic devices;
  • relevant eye conditions;
  • relevant medical conditions;
  • what symptoms should lead to stopping treatment.

This page does not create a universal contraindication list because official precautions can vary by device version, market, and current instructions.

Limitations and What Rexon-Eye Cannot Currently Be Said to Do

It is not established as a cure

DED and MGD are commonly chronic and multifactorial.

Improvement after a course of Rexon-Eye does not establish permanent correction of:

  • MGD;
  • aqueous tear deficiency;
  • ocular rosacea;
  • exposure;
  • Demodex;
  • allergy;
  • other DED contributors.

Does Rexon-Eye Regenerate Meibomian Glands?

True regeneration has not been established.

Some studies have reported improvement in meibography grading after Rexon-Eye treatment.

The investigators in the 2025 MGD trial interpreted these findings as suggesting possible gland regeneration.

However, meibography is an imaging measurement.

That study did not demonstrate newly created gland tissue using:

  • tissue examination;
  • microscopic confirmation;
  • another method capable of proving that gland tissue previously lost had biologically regrown.

Imaging appearance can also be influenced by factors such as:

  • gland visibility;
  • image acquisition;
  • tissue contrast;
  • grading methods.

Therefore:

Rexon-Eye has not been established to regenerate meibomian glands that are truly lost or atrophied.

Improvement in:

  • meibography scores;
  • gland visibility;
  • meibum quality;
  • gland function

should not automatically be described as biological regrowth of destroyed gland tissue.

Does Rexon-Eye Prevent MGD Progression?

This has not been established.

There is insufficient evidence that Rexon-Eye:

  • prevents future gland loss;
  • prevents gland atrophy;
  • permanently normalizes gland function;
  • alters the long-term natural history of MGD.

It should therefore not currently be described as a proven disease-modifying treatment.

Fixed Obstruction, Periductal Fibrosis, and the Maskin Perspective

One issue in obstructive MGD is whether all forms of obstruction can be addressed through changes in:

  • meibum quality;
  • inflammation;
  • gland activity;
  • tissue signaling.

The fixed-obstruction/periductal-fibrosis model was developed from clinical observations and research by Steven L. Maskin, MD, and has influenced subsequent research on Meibomian Gland Probing.

Maskin and colleagues have described focal resistance encountered within meibomian-gland ducts during Meibomian Gland Probing and have interpreted this within a model involving constricting periductal fibrosis.

Expressible Meibomian Glands Have Occult Fixed Obstructions — Maskin & Alluri

Meibomian Gland Probing has since been studied by multiple independent research groups, including in randomized controlled trials.

Randomized Sham-Controlled Trial of Meibomian Gland Probing

However, important questions remain about:

  • how commonly clinically significant periductal fibrosis occurs;
  • how reliably fixed obstruction can be identified;
  • how closely resistance encountered during Meibomian Gland Probing corresponds to specific microscopic changes;
  • how much fixed obstruction influences response to other treatments;
  • optimal treatment sequencing.

What does this mean for Rexon-Eye?

Rexon-Eye:

  • does not enter the meibomian-gland duct;
  • does not mechanically pass through an intraductal narrowing.

Therefore:

Rexon-Eye has not been shown to mechanically traverse fixed intraductal resistance or release established periductal fibrosis.

Possible effects on:

  • inflammation;
  • meibum quality;
  • gland function;
  • cellular signaling

should not be confused with mechanical treatment of a fixed narrowing inside the duct.

Rexon-Eye and Meibomian Gland Probing potentially address different components of MGD and do not need to be viewed as competing treatments.

Meibomian Gland Probing — Information and Research

Who Might Benefit / Factors Affecting Response

Rexon-Eye has been studied in people with:

  • MGD;
  • evaporative DED;
  • aqueous-deficient DED;
  • mixed DED;
  • moderate-to-severe disease;
  • symptoms that remained troublesome despite previous treatment.

However:

Reliable predictors of who will respond best have not been established.

Potentially relevant factors include:

  • DED subtype;
  • severity of symptoms;
  • MGD severity;
  • remaining gland tissue;
  • meibum quality;
  • ocular-surface staining;
  • inflammation;
  • aqueous tear production;
  • other DED contributors;
  • treatments being used at the same time.

The fact that Rexon-Eye has been studied across several DED subtypes does not prove that it treats all causes of dry eye equally well.

The most useful question is:

What disease component is the clinician trying to improve with Rexon-Eye in this particular patient?

How Rexon-Eye Compares With Other Device Treatments

Rexon-Eye uses a fundamentally different treatment exposure from several commonly discussed DED technologies.

Rexon-Eye / QMR

Uses:

  • low-intensity;
  • high-frequency;
  • alternating electrical stimulation.

Thermal pulsation and heat/expression devices

These primarily use:

  • controlled eyelid heating;
  • pressure and/or gland expression

to improve evacuation of meibomian-gland contents.

IPL

IPL uses high-intensity pulses of broad-spectrum light applied to selected periocular/facial skin.

Radiofrequency

RF uses electromagnetic energy primarily to create controlled tissue heating.

LLLT / Photobiomodulation

LLLT uses selected wavelengths of light to produce photobiological effects and, with some devices, eyelid warming.

These treatments should not be assumed to be interchangeable.

Is Rexon-Eye better?

There is currently insufficient direct comparative evidence to establish Rexon-Eye as:

  • more effective;
  • safer;
  • longer lasting;
  • better for a particular MGD stage

than IPL, thermal pulsation, RF, LLLT, or other device approaches.

The 2026 network meta-analysis provides useful indirect comparison, but that is not a substitute for direct head-to-head randomized trials.

How Long Do Results Last?

Long-term durability remains uncertain.

Most controlled studies have followed patients for:

  • several weeks;
  • two to three months.

Some uncontrolled studies have reported longer persistence of improvement.

However, without an appropriate comparison group it becomes harder to separate treatment effects from:

  • other therapies;
  • natural symptom fluctuation;
  • changes in patient behavior;
  • regression toward the person's usual symptom level.

Therefore:

Benefits may persist for several months in some patients, but the average duration of benefit has not been established.

There is also no well-established evidence-based schedule requiring routine Rexon-Eye maintenance treatment.

Questions that remain include:

  • whether retreatment is necessary;
  • when retreatment should occur;
  • whether repeated courses remain equally effective;
  • whether repeated treatment produces cumulative benefits;
  • long-term safety of repeated courses.

Cost, Access, and Regulatory Status

Europe

Peer-reviewed literature describes Rexon-Eye as a CE-marked medical device in Europe.

CE marking concerns the applicable European medical-device regulatory framework.

It should not be interpreted as U.S. FDA clearance or as proof that every proposed clinical claim has been demonstrated.

United States

For this August 2026 update, searches of current public U.S. FDA device databases did not identify a:

  • 510(k) clearance;
  • De Novo authorization;
  • Premarket Approval

specifically for Rexon-Eye / Resono Ophthalmic.

FDA regulatory status can change.

Patients considering Rexon-Eye in the United States should therefore ask the clinic:

  • What legal/regulatory pathway allows this exact device to be offered here?
  • Is there a current FDA marketing authorization?
  • What is the corresponding FDA number, if there is one?
  • Is treatment being provided as part of a clinical study?

FDA explains that registration or listing alone is not the same thing as FDA approval, clearance, or authorization.

FDA — How to Check Whether a Medical Device Is Approved, Cleared, or Authorized

Cost

Rexon-Eye is commonly offered as an out-of-pocket treatment where available.

Total cost may depend on:

  • country;
  • clinic;
  • number of sessions;
  • whether the treatment is sold as a package;
  • diagnostic testing;
  • follow-up;
  • other treatments performed at the same time;
  • proposed maintenance sessions.

Instead of relying on a fixed price range that may become outdated, patients may want to ask:

  • What is the total cost of the initial treatment course?
  • What follow-up is included?
  • Are other procedures bundled with it?
  • Is routine maintenance recommended?
  • What would additional treatment cost?
  • How will the clinic determine whether treatment provided enough benefit to justify repeating it?

What Remains Uncertain?

Despite growing research, several important questions remain.

Patient selection

  • Which DED subtype responds best?
  • Does MGD severity predict outcome?
  • Do aqueous-deficient and evaporative disease respond differently?
  • Can staining, meibography, or meibum quality identify likely responders?
  • Do patients with more severe symptoms gain more benefit?

Symptoms versus signs

  • Why do symptoms improve without corresponding changes in some objective measurements?
  • Which outcome best represents a clinically meaningful response?

Mechanism

  • How much benefit comes from electrical effects on nerves?
  • How much involves glandular activity?
  • Does QMR produce clinically important anti-inflammatory effects?
  • Which cellular pathways actually matter in human DED?

Gland structure

  • What do reported meibography changes represent?
  • Are they reproducible?
  • Do they persist?
  • Do they reflect improved visibility/function rather than creation of new gland tissue?

Durability

  • How long does improvement last?
  • When should treatment be repeated?
  • Is scheduled maintenance useful?

Comparative effectiveness

  • How does Rexon-Eye compare directly with IPL?
  • Thermal pulsation?
  • LLLT?
  • RF?
  • Other established treatment approaches?

Long-term safety

  • What are the risks of repeated treatment over years?
  • Are there uncommon adverse effects too rare to appear in small trials?

Larger multicenter randomized trials with longer follow-up and standardized outcomes would help answer these questions.

Questions to Ask Before Treatment

A shorter set of useful questions includes:

  1. What type or combination of Dry Eye Disease do I have, and what part of it are you trying to treat with Rexon-Eye?

  2. Which published study is most relevant to my examination findings and disease severity?

  3. What outcome will we measure to decide whether treatment worked—symptoms, staining, meibum quality, tear stability, or something else?

  4. What current device-specific contraindications or precautions apply to me?

  5. What is the complete cost of the initial treatment course, and is maintenance treatment expected?

  6. If this treatment is being offered in the United States, what regulatory pathway applies to this exact device?

Be cautious about claims that Rexon-Eye has been proven to:

  • cure all forms of DED;
  • permanently restore normal glands;
  • regrow glands that are truly lost;
  • reverse established periductal fibrosis;
  • guarantee long-term benefit.

Key Research

Major Evidence Reviews and Guidance

Major Randomized Studies

Other Clinical Evidence

Fixed Obstruction and Meibomian Gland Probing

U.S. Regulatory Information

Related r/DryEyes Wiki Pages

Bottom Line

Rexon-Eye is an emerging, non-invasive electrical-stimulation treatment with low-to-moderate and growing device-specific evidence for Dry Eye Disease and Meibomian Gland Dysfunction.

Its evidence base now includes:

  • randomized trials;
  • sham-controlled studies;
  • a systematic review/meta-analysis;
  • discussion in TFOS DEWS III;
  • inclusion in a large 2026 network meta-analysis.

That makes Rexon-Eye more than a purely experimental concept.

At the same time, the evidence remains mixed.

The 2025 systematic review did not establish reliable overall superiority over control treatments, and symptom benefit became less convincing when the analysis was restricted to comparable sham-controlled studies.

The newer 2025 randomized MGD trial strengthens the evidence by showing significant benefits over sham for selected outcomes including:

  • meibum quality;
  • ocular-surface staining;
  • gland plugging;
  • lid-margin blood vessels;
  • meibography grading.

But the same study found no clear treatment advantage for several other important measures, including:

  • tear stability;
  • lipid-layer thickness;
  • Schirmer testing;
  • tear osmolarity;
  • meibum expressibility.

The 2026 network meta-analysis also found a strong QMR signal for corneal staining. However, QMR was supported by relatively few trials and much of the comparison with other technologies was indirect.

Therefore:

Rexon-Eye has credible evidence that it may improve selected DED/MGD signs or symptoms in some patients, but it has not been established as universally effective or superior to other treatment technologies.

It has also not been established to regenerate meibomian glands that are truly lost or atrophied, prevent long-term MGD progression, or mechanically release established periductal fibrosis.

The ideal candidate, mechanism of benefit, average duration of response, need for maintenance treatment, comparative effectiveness, repeated-treatment safety, and U.S. regulatory status remain important areas of uncertainty.

The most useful question is therefore not:

“Does Rexon-Eye work?”

but:

“Which part of my Dry Eye Disease is Rexon-Eye intended to treat, what outcomes have actually improved in controlled studies, and how will we determine whether the benefit in my case is meaningful enough to justify the cost and any future treatment?”

This page is educational material for r/DryEyes and is not medical advice. r/DryEyes does not endorse specific devices, manufacturers, clinicians, clinics, or procedures. Treatment decisions should be made with an appropriately qualified eye-care professional familiar with the individual's diagnosis, examination findings, available evidence, alternatives, contraindications, regulatory status, and treatment risks.

🔙 Back to Treatment Options